181 related articles for article (PubMed ID: 32546661)
1. A Novel Approach to Safer Glucocorticoid Receptor-Targeted Anti-lymphoma Therapy via REDD1 (Regulated in Development and DNA Damage 1) Inhibition.
Lesovaya EA; Savinkova AV; Morozova OV; Lylova ES; Zhidkova EM; Kulikov EP; Kirsanov KI; Klopot A; Baida G; Yakubovskaya MG; Gordon LI; Readhead B; Dudley JT; Budunova I
Mol Cancer Ther; 2020 Sep; 19(9):1898-1908. PubMed ID: 32546661
[TBL] [Abstract][Full Text] [Related]
2. PI3K inhibitors protect against glucocorticoid-induced skin atrophy.
Agarwal S; Mirzoeva S; Readhead B; Dudley JT; Budunova I
EBioMedicine; 2019 Mar; 41():526-537. PubMed ID: 30737086
[TBL] [Abstract][Full Text] [Related]
3. Rapamycin Modulates Glucocorticoid Receptor Function, Blocks Atrophogene REDD1, and Protects Skin from Steroid Atrophy.
Lesovaya E; Agarwal S; Readhead B; Vinokour E; Baida G; Bhalla P; Kirsanov K; Yakubovskaya M; Platanias LC; Dudley JT; Budunova I
J Invest Dermatol; 2018 Sep; 138(9):1935-1944. PubMed ID: 29596905
[TBL] [Abstract][Full Text] [Related]
4. The long winding road to the safer glucocorticoid receptor (GR) targeting therapies.
Lesovaya EA; Chudakova D; Baida G; Zhidkova EM; Kirsanov KI; Yakubovskaya MG; Budunova IV
Oncotarget; 2022; 13():408-424. PubMed ID: 35198100
[TBL] [Abstract][Full Text] [Related]
5. Nutritional Sensor REDD1 in Cancer and Inflammation: Friend or Foe?
Zhidkova EM; Lylova ES; Grigoreva DD; Kirsanov KI; Osipova AV; Kulikov EP; Mertsalov SA; Belitsky GA; Budunova I; Yakubovskaya MG; Lesovaya EA
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077083
[TBL] [Abstract][Full Text] [Related]
6. REDD1 functions at the crossroads between the therapeutic and adverse effects of topical glucocorticoids.
Baida G; Bhalla P; Kirsanov K; Lesovaya E; Yakubovskaya M; Yuen K; Guo S; Lavker RM; Readhead B; Dudley JT; Budunova I
EMBO Mol Med; 2015 Jan; 7(1):42-58. PubMed ID: 25504525
[TBL] [Abstract][Full Text] [Related]
7. REDD1/DDIT4-independent mTORC1 inhibition and apoptosis by glucocorticoids in thymocytes.
Wolff NC; McKay RM; Brugarolas J
Mol Cancer Res; 2014 Jun; 12(6):867-77. PubMed ID: 24615339
[TBL] [Abstract][Full Text] [Related]
8. REDD1 (regulated in development and DNA damage 1) modulates the glucocorticoid receptor function in keratinocytes.
Chudakova DA; Trubetskoy D; Baida G; Bhalla P; Readhead B; Budunova I
Exp Dermatol; 2023 Oct; 32(10):1725-1733. PubMed ID: 37483165
[TBL] [Abstract][Full Text] [Related]
9. Glucocorticoid-mediated repression of REDD1 mRNA expression in rat fetal distal lung epithelial cells.
Otulakowski G; Duan W; Sarangapani A; Gandhi S; O'Brodovich H
Pediatr Res; 2009 May; 65(5):514-9. PubMed ID: 19127203
[TBL] [Abstract][Full Text] [Related]
10. REDD1 deletion prevents dexamethasone-induced skeletal muscle atrophy.
Britto FA; Begue G; Rossano B; Docquier A; Vernus B; Sar C; Ferry A; Bonnieu A; Ollendorff V; Favier FB
Am J Physiol Endocrinol Metab; 2014 Dec; 307(11):E983-93. PubMed ID: 25315696
[TBL] [Abstract][Full Text] [Related]
11. REDD1 is a major target of testosterone action in preventing dexamethasone-induced muscle loss.
Wu Y; Zhao W; Zhao J; Zhang Y; Qin W; Pan J; Bauman WA; Blitzer RD; Cardozo C
Endocrinology; 2010 Mar; 151(3):1050-9. PubMed ID: 20032058
[TBL] [Abstract][Full Text] [Related]
12. Sexual dimorphism in atrophic effects of topical glucocorticoids is driven by differential regulation of atrophogene REDD1 in male and female skin.
Baida G; Agarwal S; Readhead B; Dudley JT; Budunova I
Oncotarget; 2020 Jan; 11(4):409-418. PubMed ID: 32064044
[TBL] [Abstract][Full Text] [Related]
13. Combination of a selective activator of the glucocorticoid receptor Compound A with a proteasome inhibitor as a novel strategy for chemotherapy of hematologic malignancies.
Lesovaya E; Yemelyanov A; Kirsanov K; Popa A; Belitsky G; Yakubovskaya M; Gordon LI; Rosen ST; Budunova I
Cell Cycle; 2013 Jan; 12(1):133-44. PubMed ID: 23255118
[TBL] [Abstract][Full Text] [Related]
14. IL-12 inhibits glucocorticoid-induced T cell apoptosis by inducing GMEB1 and activating PI3K/Akt pathway.
Kawabe K; Lindsay D; Braitch M; Fahey AJ; Showe L; Constantinescu CS
Immunobiology; 2012 Jan; 217(1):118-23. PubMed ID: 21840619
[TBL] [Abstract][Full Text] [Related]
15. Glucocorticoid elevation of dexamethasone-induced gene 2 (Dig2/RTP801/REDD1) protein mediates autophagy in lymphocytes.
Molitoris JK; McColl KS; Swerdlow S; Matsuyama M; Lam M; Finkel TH; Matsuyama S; Distelhorst CW
J Biol Chem; 2011 Aug; 286(34):30181-9. PubMed ID: 21733849
[TBL] [Abstract][Full Text] [Related]
16. Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235.
Hall CP; Reynolds CP; Kang MH
Clin Cancer Res; 2016 Feb; 22(3):621-32. PubMed ID: 26080839
[TBL] [Abstract][Full Text] [Related]
17. Rapamycin sensitizes glucocorticoid resistant acute lymphoblastic leukemia CEM-C1 cells to dexamethasone induced apoptosis through both mTOR suppression and up-regulation and activation of glucocorticoid receptor.
Guo X; Zhou CY; Li Q; Gao J; Zhu YP; Gu L; Ma ZG
Biomed Environ Sci; 2013 May; 26(5):371-81. PubMed ID: 23611130
[TBL] [Abstract][Full Text] [Related]
18. Glucocorticoid regulation of amino acid transport in primary human trophoblast cells.
Vaughan OR; Powell TL; Jansson T
J Mol Endocrinol; 2019 Nov; 63(4):239-248. PubMed ID: 31505460
[TBL] [Abstract][Full Text] [Related]
19. Selective Activator of the Glucocorticoid Receptor Compound A Dissociates Therapeutic and Atrophogenic Effects of Glucocorticoid Receptor Signaling in Skin.
Klopot A; Baida G; Bhalla P; Haegeman G; Budunova I
J Cancer Prev; 2015 Dec; 20(4):250-9. PubMed ID: 26734587
[TBL] [Abstract][Full Text] [Related]
20. Dexamethasone represses signaling through the mammalian target of rapamycin in muscle cells by enhancing expression of REDD1.
Wang H; Kubica N; Ellisen LW; Jefferson LS; Kimball SR
J Biol Chem; 2006 Dec; 281(51):39128-34. PubMed ID: 17074751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
